ORMP News and Press, Oramed Pharmaceuticals Inc. From 10/07/22

Oramed Pharmaceuticals ( NASDAQ: ORMP ) said oral COVID-19 vaccine candidate met the main and secondary goals of safety and immunogenicity as per preliminary data from a phase 1 trial. Oramed's unit Oravax Medical's oral vaccine candidate combines Oramed POD te...

Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine PR Newswire Primary and secondary endpoints of safety and immunogenicity met Oral vaccine elicited a potentially protective IgG response with significant se...

Summary Results from Oramed Pharmaceuticals's first phase 3 study ORA-D-013-1, using ORMD-0801 for the treatment of patients with Type 2 Diabetes, is expected January 2023. Results from the ongoing Cohorts A and B, using Oravax for Covid-19, are going to be read out Q3 and Q4 of 2...

Oramed Pharmaceuticals ( NASDAQ: ORMP ) on Tuesday said a phase 2 trial assessing its oral insulin candidate to reduce liver fat content in type 2 diabetes patients with liver disease non-alcoholic steatohepatitis (NASH) met its main goal. The insulin candidate, called ORM...

Oramed Reports Positive Top-Line Results from Phase 2 NASH Trial with its ORMD-0801, Oral Insulin Candidate PR Newswire Primary endpoint met: ORMD-0801 was safe and well tolerated Secondary endpoint met: ORMD-0801 showed clinically meaningful reduction of liv...

Oramed Pharmaceuticals Inc. ( NASDAQ: ORMP ), a company focused on treatments for diabetes, announced a non-binding agreement with Medicox Co., Ltd. granting the latter exclusive right and license to seek regulatory nod and distribute ORMP’s oral insulin capsule ORMD-08...

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference PR Newswire NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focu...

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial PR Newswire - ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol - ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 ...

Shares of the clinical-stage biotech Oramed Pharmaceuticals (NASDAQ: ORMP) are having a banner day today. Specifically, the company's stock price rose by as much as 40% on extremely high volume early on in Tuesday's trading session. The biotech's shares have cooled off as the day ha...

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...